More than 200 brands spoke out in the week that followed Hamas’ terrorist attacks against Israel a year ago. Yet companies ...

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...

Shares of Pfizer (NYSE: PFE) have been stuck in the mud since December 2022, with its shares down more than 45% over that ...

Pfizer CEO Albert Bourla plans to meet activist investor Starboard Value, the Financial Times reported on Tuesday, citing ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...

Pfizer Inc. CEO Albert Bourla is set to meet with activist investor Starboard Value amid growing pressure to revitalize the ...

Pfizer CEO is set to meet with activist investor Starboard Value after the investor acquired a $1 billion stake in the ...

(Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age ...

JMP Securities analyst Roy Buchanan reiterated a Buy rating on Enanta Pharmaceuticals (ENTA – Research Report) today and set a price ...

Starboard has a roughly $1 billion stake in the drugmaker and approached former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

Albert Bourla, the CEO of pharmaceutical company Pfizer ($PFE), plans to meet with activist investor Starboard Value in ...